Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Cardiologique du Nord
With
Campus Bio-Medico University
Henri Mondor University Hospital
Hokkaido University
University of Genova
The target population enrolled in the registry includes patients with moderate to severe secondary mitral regurgitation due to cardiomyopathy of either ischemic or non-ischemic etiology who have had TEER or standard surgical procedure of their mitral valves with or without CABG. Individuals were adequately treated per applicable standards, including for coronary artery disease, LV dysfunction, mitral regurgitation, and heart failure. Patients enrolled in the studies were NYHA functional class II, III, or outpatient NYHA IV.
Four groups of patients are included in the study. Patients who were managed with TEER, patients who received mitral valve replacement and recipients of mitral valve repair who underwent surgery with the use of restrictive annuloplasty alone or combined with subvalvular repair. Four groups of patients are included in the study. Patients who were managed with TEER, patients who received mitral valve replacement, and those who received mitral valve repair who underwent surgery with the use of restrictive annuloplasty alone or combined with subvalvular repair
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult
Ischemic NoIschemic cardiomyopathy
EROA\> 0,2 cm2 or Regurgitant Volume \> 30 ml (ESC guidelines).
EROA ≥ 0.4 cm2 with tethering (ACC/AHA)
MR Grade 3/4
Eligible for TEE, surgical repair and replacement of mitral valve
Coronary artery disease with or without the need for coronary revascularization
Average value LVEDD 62 mm LVEF 42%
You may not be if
Pediatric
Any echocardiographic evidence of structural (chordal or leaflet) mitral-valve disease